Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Jeevan Scienti.
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 7.93 | 10.39 | 8.06 | 10.13 | 11.07 | 12.88 | 11.40 | 12.51 | 10.06 | 8.80 | 12.38 | 19.07 | 21.29 |
| Expenses + | 8.96 | 8.36 | 7.46 | 9.12 | 10.09 | 9.65 | 8.90 | 10.44 | 10.44 | 10.58 | 10.31 | 13.84 | 17.00 |
| Operating Profit | -1.03 | 2.03 | 0.60 | 1.01 | 0.98 | 3.23 | 2.50 | 2.07 | -0.38 | -1.78 | 2.07 | 5.23 | 4.29 |
| OPM % | -12.99% | 19.54% | 7.44% | 9.97% | 8.85% | 25.08% | 21.93% | 16.55% | -3.78% | -20.23% | 16.72% | 27.43% | 20.15% |
| Other Income + | 0.27 | 0.30 | 0.26 | -0.11 | 0.23 | 0.11 | 0.16 | 0.23 | 0.15 | 0.33 | 0.20 | 0.14 | 0.29 |
| Interest | 0.28 | 0.23 | 0.26 | 0.15 | 0.33 | 0.33 | 0.45 | 0.43 | 0.55 | 0.54 | 0.55 | 0.54 | 0.41 |
| Depreciation | 1.42 | 1.47 | 1.43 | 1.40 | 1.64 | 1.51 | 1.49 | 1.48 | 1.77 | 1.74 | 1.69 | 1.60 | 1.61 |
| Profit before tax | -2.46 | 0.63 | -0.83 | -0.65 | -0.76 | 1.50 | 0.72 | 0.39 | -2.55 | -3.73 | 0.03 | 3.23 | 2.56 |
| Tax % | -6.10% | 19.05% | -25.30% | -24.62% | -3.95% | 31.33% | 65.28% | 89.74% | -50.59% | -13.67% | 66.67% | 25.70% | 28.52% |
| Net Profit + | -2.31 | 0.51 | -0.61 | -0.49 | -0.73 | 1.03 | 0.25 | 0.05 | -1.26 | -3.22 | 0.01 | 2.40 | 1.84 |
| EPS in Rs | -1.49 | 0.34 | -0.39 | -0.31 | -0.47 | 0.70 | 0.16 | 0.07 | -0.82 | -1.96 | -0.06 | 0.90 | 0.81 |
Financials of Jeevan Scienti.
Annual income statement trend
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 17.39 | 18.21 | 20.39 | 26.13 | 23.94 | 46.90 | 67.79 | 36.18 | 39.65 | 46.84 | 61.54 |
| Expenses + | 15.59 | 15.01 | 16.96 | 20.27 | 30.02 | 29.41 | 51.02 | 34.82 | 35.01 | 39.37 | 51.74 |
| Operating Profit | 1.80 | 3.20 | 3.43 | 5.86 | -6.08 | 17.49 | 16.77 | 1.36 | 4.64 | 7.47 | 9.80 |
| OPM % | 10.35% | 17.57% | 16.82% | 22.43% | -25.40% | 37.29% | 24.74% | 3.76% | 11.70% | 15.95% | 15.92% |
| Other Income + | 0.37 | 0.58 | 0.92 | 1.00 | 2.50 | 2.39 | 5.91 | 1.07 | 0.67 | 0.65 | 0.97 |
| Interest | 1.28 | 1.54 | 1.87 | 2.36 | 3.04 | 2.26 | 0.96 | 1.04 | 0.98 | 1.82 | 2.04 |
| Depreciation | 0.68 | 1.23 | 2.12 | 3.13 | 3.92 | 3.97 | 3.69 | 5.07 | 5.93 | 6.25 | 6.64 |
| Profit before tax | 0.21 | 1.01 | 0.36 | 1.37 | -10.54 | 13.65 | 18.03 | -3.68 | -1.60 | 0.05 | 2.09 |
| Tax % | 104.76% | 10.89% | 69.44% | 18.25% | -18.60% | 13.99% | 33.78% | -16.58% | -17.50% | -20.00% | 50.72% |
| Net Profit + | -0.01 | 0.90 | 0.11 | 1.11 | -8.59 | 11.74 | 11.94 | -3.07 | -1.33 | 0.05 | 1.03 |
| EPS in Rs | -0.02 | 0.97 | 0.10 | 0.73 | -5.61 | 7.67 | 7.80 | -1.97 | -0.84 | 0.08 | 0.58 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 6.52% | 15.38% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials of Jeevan Scienti.
Capital structure and asset base
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.04 | 9.28 | 11.46 | 15.30 | 15.30 | 15.30 | 15.30 | 15.48 | 15.48 | 15.83 | 19.92 |
| Reserves | -2.27 | 7.60 | 10.55 | 16.53 | 7.92 | 19.72 | 35.28 | 32.71 | 32.95 | 34.11 | 52.02 |
| Borrowings + | 11.08 | 8.45 | 18.78 | 18.15 | 17.95 | 10.34 | 12.55 | 10.10 | 13.41 | 20.58 | 21.28 |
| Other Liabilities + | 5.56 | 5.56 | 8.59 | 11.32 | 12.70 | 20.62 | 14.75 | 7.63 | 6.03 | 7.77 | 13.37 |
| Total Liabilities | 20.41 | 30.89 | 49.38 | 61.30 | 53.87 | 65.98 | 77.88 | 65.92 | 67.87 | 78.29 | 106.59 |
| Fixed Assets + | 8.67 | 16.35 | 28.17 | 32.59 | 30.54 | 27.38 | 19.07 | 24.97 | 26.66 | 34.55 | 36.08 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.90 | 2.81 | 4.71 | 4.71 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.98 |
| Other Assets + | 11.74 | 14.54 | 21.21 | 28.71 | 23.33 | 38.60 | 58.81 | 39.05 | 38.40 | 39.03 | 62.82 |
| Total Assets | 20.41 | 30.89 | 49.38 | 61.30 | 53.87 | 65.98 | 77.88 | 65.92 | 67.87 | 78.29 | 106.59 |
Financials of Jeevan Scienti.
Operating, investing and financing cash movement
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 3.55 | -5.62 | 5.65 | 4.04 | -0.01 | 4.95 | 19.56 | -6.41 | 2.89 | 10.07 | |
| Cash from Investing Activity + | -3.63 | -8.90 | -14.35 | -7.87 | -1.90 | -0.80 | -1.20 | -6.93 | -11.53 | -15.62 | |
| Cash from Financing Activity + | 0.23 | 14.57 | 9.86 | 6.08 | 0.44 | -0.13 | 5.67 | -9.54 | 2.35 | 5.24 | |
| Net Cash Flow | 0.15 | 0.05 | 1.17 | 2.25 | -1.47 | 4.02 | 24.03 | -22.88 | -6.29 | -0.30 | |
| Free Cash Flow | -0.08 | -14.52 | -8.70 | -3.83 | -1.91 | 4.15 | 17.33 | -14.57 | -9.14 | -5.96 | |
| CFO/OP | 197% | -176% | 165% | 69% | 32% | 39% | 153% | -269% | 101% | 135% |
Financials of Jeevan Scienti.
Working capital efficiency and return ratios
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 151.96 | 227.10 | 291.79 | 205.20 | 104.29 | 112.46 | 40.97 | 117.83 | 113.14 | 124.21 | 122.71 |
| Inventory Days | 72.11 | 105.50 | 104.15 | 155.61 | 226.63 | ||||||
| Days Payable | 98.78 | 322.56 | 205.43 | 305.45 | 458.49 | ||||||
| Cash Conversion Cycle | 151.96 | 227.10 | 291.79 | 205.20 | 104.29 | 112.46 | 14.30 | -99.23 | 11.85 | -25.63 | -109.15 |
| Working Capital Days | 52.05 | 90.60 | 35.44 | -3.07 | -100.78 | 37.36 | 10.18 | 110.67 | 137.35 | 128.19 | 121.41 |
| ROCE % | 12.69% | 6.75% | 8.22% | -16.39% | 36.77% | 27.58% | -4.34% | -1.03% | 2.80% | 5.01% |
Volume-led growth with inpatient (IP) volumes up 39% and outpatient (OP) volumes up 26% year-on-year. Key concall takeaways from Manipal Health Enterprises…
IHH plans to increase its stake in Fortis to over 50% within 3-5 years, supporting long-term strategic growth. Key concall takeaways from Fortis Healthcare…
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…